J. Russel Denton - 03 Mar 2025 Form 4 Insider Report for Caris Life Sciences, Inc.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
23 Jun 2025, 18:34:51 UTC
Next SEC filing
17 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ J. Russel Denton

Key filing fact

J. Russel Denton filed Form 4 for Caris Life Sciences, Inc. on 23 Jun 2025.

Key facts

  • This page summarizes J. Russel Denton's Form 4 filing for Caris Life Sciences, Inc..
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 23 Jun 2025, 18:34.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: -$4,273,578.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002071923 Primary reporting owner

Denton John Russel

Relationship
Senior Vice President, General Counsel, and Secretary
Address
C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature
/s/ J. Russel Denton
Signature date
23 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Disposed to Issuer

Transaction value
$4,431,078
Shares
-238,230
Change %
-93%
Price
$18.60
Shares after
16,770
Date
03 Mar 2025
Ownership
Direct
Footnotes
F1, F2
CAI transaction

Common Stock

Award

Transaction value
$0
Shares
+99,321
Change %
+592%
Price
$0.000000
Shares after
116,091
Date
18 Jun 2025
Ownership
Direct
Footnotes
F3
CAI transaction

Common Stock

Purchase

Transaction value
$157,500
Shares
+7,500
Change %
+6.5%
Price
$21.00
Shares after
123,591
Date
20 Jun 2025
Ownership
Direct
CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,000
Date
03 Mar 2025
Ownership
By Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAI transaction Derivative

Stock Option

Award

Transaction value
$0
Shares
+255,000
Change %
Price
$0.000000
Shares after
255,000
Date
03 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
255,000
Exercise price
$18.60
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note.

Footnote F2

These securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

Footnote F3

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Footnote F4

The stock option vested 60% at grant and will vest 20% on September 1, 2025 and 20% on September 1, 2026. These securities were previously reported on the Reporting Person's Form 3.

SEC remarks

Senior Vice President, General Counsel, and Secretary

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .